Customers Endorse Elsevier’s Inteleos on the Eve of First Anniversary

Elsevier, a world-leading healthcare and scientific publisher, announced today the first year anniversary of Inteleos, its drug tracking and analysis tool that supports decision-making and business strategy for business intelligence professionals.

Inteleos has received overwhelmingly positive responses from the industry since its launch. The survey results provide further validation that Inteleos is the most intuitive, flexible tool for drug pipeline research, tracking and analysis.

In addition to gauging customer satisfaction, the survey solicited feedback on new product development. "I am very pleased that so many Inteleos customers are willing to endorse the product, but I’m even more enthusiastic about the prospect of applying their feedback to the next generation of development for Inteleos, says Health Sciences CEO, Brian Nairn.

The Inteleos development and editorial teams will continue to build on the product’s strengths and provide enhanced indexing to meet today’s scientific challenges. The coverage of biologics, together with the most comprehensive coverage of FDA (and soon EMEA) regulatory filings in the drug pipeline product sector, makes Inteleos an invaluable resource.

The anniversary is the first in a series of milestones for Inteleos. “By listening to our customers and other business intelligence professionals, we have been able to create an exciting development plan for Inteleos that will be rolled out throughout 2007,” reports Director of Emerging Products, Julie Gordon. “New content and enhanced functionality will make it even easier for our customers to make informed business decisions.”